# Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration

> **NCT02802657** · PHASE4 · UNKNOWN · sponsor: **Xiaodong Sun** · enrollment: 141 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **PROCEDURE:** Treat-and-Extend regimen
- **PROCEDURE:** Pro Re Nata
- **DRUG:** Conbercept

## Key facts

- **NCT ID:** NCT02802657
- **Lead sponsor:** Xiaodong Sun
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2020-05-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802657, "Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02802657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*